The DOI matches its Crossref record; 44 of the 46 references it cites were found in a registry or an index.
Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features
Open accessAbstract
Background & aims Agents that induce an immune response against tumors by altering T-cell regulation have increased survival times of patients with advanced-stage tumors, such as melanoma or lung cancer. We aimed to characterize molecular features of immune cells that infiltrate hepatocellular carcinomas (HCCs) to determine whether these types of agents might be effective against liver tumors.Methods We analyzed HCC samples from 956 patients. We separated gene expression profiles from tumor, stromal, and immune cells using a non-negative matrix factorization algorithm. We then analyzed the gene expression pattern of inflammatory cells in HCC tumor samples. We correlated expression patterns with the presence of immune cell infiltrates and immune regulatory molecules, determined by pathology and immunohistochemical analyses, in a training set of 228 HCC samples. We validated the correlation in a validation set of 728 tumor samples. Using data from 190 tumors in the Cancer Genome Atlas, we correlated immune cell gene expression profiles with numbers of chromosomal aberrations (based on single-nucleotide polymorphism array) and mutations (exome sequence data).Results We found approximately 25% of HCCs to have markers of an inflammatory response, with high expression levels of the CD274 molecule (programmed death-ligand 1) and programmed cell death 1, markers of cytolytic activity, and fewer chromosomal aberrations. We called this group of tumors the Immune class. It contained 2 subtypes, characterized by markers of an adaptive T-cell response or exhausted immune response. The exhausted immune response subclass expressed many genes regulated by transforming growth factor beta 1 that mediate immunosuppression. We did not observe any differences in numbers of mutations or expression of tumor antigens between the immune-specific class and other HCCs.Conclusions In an analysis of HCC samples from 956 patients, we found almost 25% to express markers of an inflammatory response. We identified 2 subclasses, characterized by adaptive or exhausted immune responses. These findings indicate that some HCCs might be susceptible to therapeutic agents designed to block the regulatory pathways in T cells, such as programmed death-ligand 1, programmed cell death 1, or transforming growth factor beta 1 inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Inflamed tumours constitute ~30% of HCCs and exhibit extensive immune cell infiltration and immune activity, detected as increased expression of immune checkpoints (such as PD-1 or its ligand PD-L1), activation of IFN signalling and a low burden of large chromosomal alterations70,71,78.”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [71]
The cited source says what the claim attributes to it.
In the citing paper
“Furthermore, a high TMB does not correlate with increased immune infiltration70,71.”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [71]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Self-citationSafety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Inferring tumour purity and stromal and immune cell admixture from expression data
Yoshihara, K., Shahmoradgoli, M., Martínez, E., Vegesna, R., Kim, H., Torres-Garcia, W., Treviño, V., Shen, H., Laird, P. W., Levine, D. A., et al. (2013) · Nature Communications · doi:10.1038/ncomms3612 · Cited by 9,778
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Murray, C. J. L., Vos, T., Lozano, R., Naghavi, M., Flaxman, A. D., Michaud, C., Ezzati, M., Shibuya, K., Salomon, J. A., Abdalla, S., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61689-4 · Cited by 8,888
Herbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198
Sorafenib in Advanced Hepatocellular Carcinoma
정, 재. (2008) · Cited by 5,586
Charoentong, P., Finotello, F., Angelova, M., Mayer, C., Efremova, M., Rieder, D., Hackl, H., & Trajanoski, Z. (2017) · Cell Reports · doi:10.1016/j.celrep.2016.12.019 · Cited by 5,041
Flagged first, then by citations
2 of the 46 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 301–400 of 1,000
Immunomodulation by Inflammation during Liver and Gastrointestinal Tumorigenesis and Aging
Nagai, N., Kudo, Y., Aki, D., Nakagawa, H., & Taniguchi, K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22052238 · Cited by 30
PD-1 Blockade for Hepatocellular Carcinoma: Current Research and Future Prospects
D’Alessio, A., Rimassa, L., Cortellini, A., & Pinato, D. J. (2021) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s284440 · Cited by 29
Hatanaka, T., Naganuma, A., Hiraoka, A., Tada, T., Hirooka, M., Kariyama, K., Tani, J., Atsukawa, M., Takaguchi, K., Itobayashi, E., et al. (2022) · Cancer Medicine · doi:10.1002/cam4.5294 · Cited by 26
Xie, Z., Huang, J., Li, Y., Zhu, Q., Huang, X., Chen, J., Wei, C., Luo, S., Yang, S., & Gao, J. (2023) · Scientific Reports · doi:10.1038/s41598-023-46132-w · Cited by 29
Dimensions of hepatocellular carcinoma phenotypic diversity
Désert, R., Nieto, N., & Musso, O. C. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i40.4536 · Cited by 32
Fujita, M., Chen, M.-J. M., Siwak, D. R., Sasagawa, S., Oosawa-Tatsuguchi, A., Arihiro, K., Ono, A., Miura, R., Maejima, K., Aikata, H., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34249-x · Cited by 24
Wang, K., Wu, J., Zhao, Y., Zheng, B. J., Shen, S., Wang, R., Zhang, Y., Wang, H., Chen, L., & Qiu, X. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216690 · Cited by 26
Biomarkers in Hepatobiliary Cancers: What Is Useful in Clinical Practice?
Boilève, A., Hilmi, M., Delaye, M., Tijeras‐Raballand, A., & Neuzillet, C. (2021) · Cancers · doi:10.3390/cancers13112708 · Cited by 27
The spatial distribution of immune cell subpopulations in hepatocellular carcinoma
Wang, P., Hu, Z., Zhou, S., Yu, S., Mao, L., Su, S., Jia, L., Ren, N., & Huang, X. (2021) · Cancer Science · doi:10.1111/cas.15202 · Cited by 26
A clinical and pathological update on hepatocellular carcinoma
Renne, S., & di Tommaso, L. (2022) · Journal of Liver Cancer · doi:10.17998/jlc.2022.03.18 · Cited by 24
Frontline therapy for advanced hepatocellular carcinoma: an update
Akce, M., El‐Rayes, B. F., & Bekaii‐Saab, T. (2022) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848221086126 · Cited by 26
Strategies for improving the efficacy of immunotherapy in hepatocellular carcinoma
Zhu, Y., & Qin, L. (2022) · Hepatobiliary & pancreatic diseases international · doi:10.1016/j.hbpd.2022.08.003 · Cited by 26
Peng, W., Bai, S., Zheng, M., Chen, W., Li, Y., Yang, Y., Zhao, Y., Xiong, S., Wang, R., & Cheng, B. (2023) · Translational Oncology · doi:10.1016/j.tranon.2023.101651 · Cited by 26
Xing, R. S., Mei, J., Zuo, Z., Zou, H., Yu, X.-J., Xu, J., Guo, R., Wei, W., & Zheng, L. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102298 · Cited by 27
Cao, D., Chen, M., Zhang, Q.-F., Zhou, Y.-F., Zhang, M., Mai, S., Zhang, Y., Chen, M., Li, X., & Wang, H. (2020) · Aging · doi:10.18632/aging.103395 · Cited by 26
Borhani, A. A., Catania, R., Velichko, Y., Hectors, S. J. C. G., Taouli, B. A., & Lewis, S. C. (2021) · Abdominal Radiology · doi:10.1007/s00261-021-03085-w · Cited by 25
Prospects and Challenges for T Cell-Based Therapies of HCC
Woller, N., Engelskircher, S. A., Wirth, T. C., & Wedemeyer, H. H. (2021) · Cells · doi:10.3390/cells10071651 · Cited by 25
Zhao, W., Jiang, L., Fang, T., Fang, F., Liu, Y., Zhao, Y., You, Y., Zhou, H., Su, X., Wang, J., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.747282 · Cited by 25
Wang, Y., Li, Z., Huang, Z., Yu, X., Zheng, L., & Xu, J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.774823 · Cited by 25
Downregulation of TPX2 impairs the antitumor activity of CD8+ T cells in hepatocellular carcinoma
Wang, X., Wang, J., Shen, H., Luo, Z., & Xiao-jie, L. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-04645-8 · Cited by 23
Zhang, Z., Li, C., Liao, W., Huang, Y., & Wang, Z. (2022) · Cancers · doi:10.3390/cancers14153619 · Cited by 25
Chen, M., Wu, G., Hua, S., Zhao, Z., Li, K., & Luo, M. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.907859 · Cited by 25
Mechanisms of Resistance to Immunotherapy in Hepatocellular Carcinoma
Manfredi, G. F., Celsa, C., John, C., Jones, C., Acuti, N., Scheiner, B., Fulgenzi, C. A. M., Korolewicz, J., Pinter, M., Gennari, A., et al. (2023) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s291553 · Cited by 30
Kudo, M. (2021) · HepatoBiliary Surgery and Nutrition · doi:10.21037/hbsn-20-707 · Cited by 25
Liu, X., Zhang, K., Kaya, N. A., Jia, Z., Wu, D., Chen, T., Liu, Z., Zhu, S., Hillmer, A. M., Wüestefeld, T., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-47541-9 · Cited by 27
Shimoni, Y. (2018) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1006026 · Cited by 24
Yoon, S.-H., Choi, S.-W., Nam, S. W., Lee, K. B., & Nam, J. (2021) · npj Precision Oncology · doi:10.1038/s41698-021-00167-2 · Cited by 22
Tumor-Intrinsic Mechanisms Regulating Immune Exclusion in Liver Cancers
Lindblad, K. E., de Galarreta, M. R., & Lujambio, A. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.642958 · Cited by 25
Wang, Z., Xu, B., Wang, L.-N., Zhu, X., Huang, C., Shen, Y., Li, H., Li, M., Zhou, J., Fan, J., et al. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.111863 · Cited by 25
Molecular insight into T cell exhaustion in hepatocellular carcinoma
Zhu, Y., Tan, H., Wang, J., Zhuang, H., Zhao, H., & Lu, X. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107161 · Cited by 28
Leveraging radiomics and AI for precision diagnosis and prognostication of liver malignancies
Haghshomar, M., Rodrigues, D., Kalyan, A., Velichko, Y., & Borhani, A. A. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1362737 · Cited by 23
Hu, N., Li, H., Tao, C., Xiao, T., & Rong, W. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25115584 · Cited by 28
Interventional Oncology Meets Immuno-oncology: Combination Therapies for Hepatocellular Carcinoma
Bitar, R. D., Salem, R., Finn, R. S., Greten, T. F., Goldberg, S. N., & Chapiro, J. (2024) · Radiology · doi:10.1148/radiol.232875 · Cited by 25
Lu, D., Bai, X., Zou, Q., Gan, Z., & Lv, Y. (2020) · Oncology Letters · doi:10.3892/ol.2020.11844 · Cited by 23
Guardascione, M., & Toffoli, G. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176302 · Cited by 24
Wong, M., Kim, J. T., Cox, B. K., Larson, B. K., Kim, S., Waters, K. M., Vail, E., & Guindi, M. M. (2021) · Hepatic Oncology · doi:10.2217/hep-2020-0034 · Cited by 22
Singh, D., Khan, M. A., & Siddique, H. R. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.114955 · Cited by 22
Guo, Y., Yang, J., Ren, K., Tian, X., Gao, H., Tian, X., Zhang, X., & Kan, Q. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.861525 · Cited by 23
Mutational signatures and processes in hepatobiliary cancers
Zhuravleva, E., O’Rourke, C. J., & Andersen, J. B. (2022) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-022-00587-w · Cited by 23
Survival impact of immune cells infiltrating peritumoral area of hepatocellular carcinoma
Yusa, T., Yamashita, Y., Okabe, H., Nakao, Y., Itoyama, R., Kitano, Y., Kaida, T., Miyata, T., Mima, K., Imai, K., et al. (2022) · Cancer Science · doi:10.1111/cas.15437 · Cited by 24
Qin, M., Chen, G., Hou, J., Wang, L., Wang, Q., Wang, L., Jiang, D., Hu, Y., Xie, B., Chen, J., et al. (2022) · Bioengineered · doi:10.1080/21655979.2022.2162660 · Cited by 24
Li, C., Hsu, C., Lin, Y., Ho, M., Hu, R., Chen, C., Ho, T.-C., Lin, Y., Tsai, S., Tzeng, S., et al. (2023) · Liver Cancer · doi:10.1159/000530699 · Cited by 23
Current Landscape of Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma
Ruff, S. M., Manne, A., Cloyd, J. M., Dillhoff, M., Ejaz, A. M., & Pawlik, T. M. (2023) · Current Oncology · doi:10.3390/curroncol30060439 · Cited by 23
Ahn, B., Ahn, H., Shin, J., Jun, E., Koh, E., Ryu, Y., Kim, S., Sung, C. O., Shim, J. H., Hong, J., et al. (2024) · Liver International · doi:10.1111/liv.15865 · Cited by 24
Wnt/β-catenin signaling pathway in liver biology and tumorigenesis
Matsumoto, S., & Kikuchi, A. (2024) · In Vitro Cellular & Developmental Biology - Animal · doi:10.1007/s11626-024-00858-7 · Cited by 26
Alqahtani, S. A., Sanai, F. M., Alolayan, A. A. M., Abaalkhail, F. A., Alsuhaibani, H., Hassanain, M. M., Alhazzani, W. A., Alsuhaibani, A. A., Algarni, A. A., Forner, A., et al. (2020) · Saudi Journal of Gastroenterology · doi:10.4103/sjg.sjg_477_20 · Cited by 24
Torres, M. C. P., Lai, Q., Piscaglia, F., Caturelli, E., Cabibbo, G., Biasini, E., Pelizzaro, F., Marra, F., Trevisani, F., & Giannini, E. G. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10153201 · Cited by 23
Metabolic mechanisms of immunotherapy resistance
Cabezón‐Gutiérrez, L., Palka-Kotlowska, M., Custodio‐Cabello, S., Chacón-Ovejero, B., & Pacheco-Barcía, V. (2025) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2025.1002297 · Cited by 26
WNT–β-catenin signalling in hepatocellular carcinoma: from bench to clinical trials
Lehrich, B. M., & Monga, S. P. (2025) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-025-01127-y · Cited by 27
Kwon, S. M., Lee, Y., Min, S., Woo, H. G., Wang, H.-J., & Yoon, G. (2020) · iScience · doi:10.1016/j.isci.2020.101247 · Cited by 22
Qu, W., Tian, M., Qiu, J.-T., Guo, Y., Tao, C., Liu, W., Tang, Z., Qian, K., Wang, Z.-X., Li, X., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.968202 · Cited by 21
Ailia, M. J., Heo, J., & Yoo, S. Y. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076495 · Cited by 22
Sankar, K. N., Pearson, A. N., Worlikar, T., Perricone, M. D., Holcomb, E. A., Mendiratta‐Lala, M., Xu, Z., Bhowmick, N. A., & Green, M. D. (2023) · Translational Gastroenterology and Hepatology · doi:10.21037/tgh-23-11 · Cited by 22
Delineating the interplay between oncogenic pathways and immunity in anaplastic Wilms tumors
Su, X., Lu, X., Bazai, S. K., Dainese, L., Verschuur, A. C., Dumont, B., Mouawad, R., Xu, L., Cheng, W., Yan, F., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-43290-3 · Cited by 22
Lehrich, B. M., & Delgado, E. R. (2024) · Organogenesis · doi:10.1080/15476278.2024.2313696 · Cited by 24
Shi, Y., Men, X., Li, X., Yang, Z., & Wen, H. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106351 · Cited by 21
Zhang, P., Wan, Y., Ma, J., Gong, J., Zhong, Z., Cui, Y., Zhang, H., Da, Y., Ma, J., Li, C., et al. (2024) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-024-03717-2 · Cited by 21
Lehrich, B. M., Tao, J., Liu, S., Hirsch, T. Z., Yasaka, T. M., Cao, C., Delgado, E. R., Guan, X., Lu, S., Pan, L., et al. (2024) · JHEP Reports · doi:10.1016/j.jhepr.2024.101186 · Cited by 23
Multiplatform Genomic Roadmap of Hepatocellular Carcinoma: A Matter of Molecular Heterogeneity
Woo, H. G., & Kim, Y. J. (2018) · Hepatology · doi:10.1002/hep.29925 · Cited by 21
Williams, M., Liu, X., Zhang, Y., Reske, J. J., Bahal, D., Gohl, T. G., Hollern, D. P., Ensink, E., Kiupel, M., Luo, R., et al. (2020) · Oncogene · doi:10.1038/s41388-020-1256-x · Cited by 20
Lin, Z., Lu, D., Wei, X., Wang, J., & Xu, X. (2020) · PubMed Central · Cited by 21
Epidemiology, mutational landscape and staging of hepatocellular carcinoma.
Fenton, S. E., Burns, M. C., & Kalyan, A. (2021) · Chinese Clinical Oncology · doi:10.21037/cco-20-162 · Cited by 18
Kudo, M. (2021) · Liver Cancer · doi:10.1159/000514194 · Cited by 21
Yin, X., Wu, T., Lan, Y., & Yang, W. (2022) · Bioscience Reports · doi:10.1042/bsr20212304 · Cited by 22
Repáraz, D., Aparicio, B., Llópiz, D., Hervás‐Stubbs, S., & Sarobe, P. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23042022 · Cited by 24
Hong, S. E., Kneissl, J., Cho, A., Kim, M. J., Park, S., Lee, J., Woo, S., Kim, S., Kim, J., Kim, S. Y., et al. (2022) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2021-108307 · Cited by 23
Could We Predict the Response of Immune Checkpoint Inhibitor Treatment in Hepatocellular Carcinoma?
Lee, C., Chan, S., & Chon, H. (2022) · Cancers · doi:10.3390/cancers14133213 · Cited by 19
Huang, N., Zhang, J., Kuang, S., Li, Z., Zhao, H., Wu, J., Liu, M., & Wang, L. (2023) · Cancer Medicine · doi:10.1002/cam4.5597 · Cited by 21
Immunotherapy and the Combination with Targeted Therapies for Advanced Hepatocellular Carcinoma
Laface, C., Ranieri, G., Maselli, F. M., Ambrogio, F., Foti, C., Ammendola, M., Laterza, M., Cazzato, G., Memeo, R., Mastrandrea, G., et al. (2023) · Cancers · doi:10.3390/cancers15030654 · Cited by 21
Feng, M., Wang, F., Liu, X., Hao, T., Zhang, N., Deng, M., Pan, Y., & Kong, R. (2023) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2023.0019 · Cited by 23
Diethylnitrosamine Induction of Hepatocarcinogenesis in Mice
Sotty, J., Bablon, P., Weiss, P.-H., & Soussan, P. (2024) · Methods in molecular biology · doi:10.1007/978-1-0716-3694-7_2 · Cited by 21
Désert, R., Giannone, F., Saviano, A., Hoshida, Y., Heikenwälder, M. F., Nahon, P., & Baumert, T. F. (2025) · npj gut and liver. · doi:10.1038/s44355-025-00018-y · Cited by 23
Improving surgical treatments for hepatocellular carcinoma
Malik, A. K., Geh, D., Evans, T. R. J., Chow, P. K. H., Mann, D. A., & White, S. A. (2025) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-025-01143-y · Cited by 24
Immunotherapy with Checkpoint Inhibitors for Hepatocellular Carcinoma: Where Are We Now?
Tovoli, F., Lorenzo, S. D., & Trevisani, F. (2020) · Vaccines · doi:10.3390/vaccines8040578 · Cited by 20
Choi, J. H., Kwon, S. M., Moon, S. U., Yoon, S., Shah, M., Lee, B. G., Yang, J., Park, Y. N., Wang, H.-J., & Woo, H. G. (2021) · Liver International · doi:10.1111/liv.15026 · Cited by 20
Xu, Y., Zhang, Z., Xu, D., Yang, X. L., Zhou, L., & Zhu, Y. (2021) · Cancer Cell International · doi:10.1186/s12935-021-02108-2 · Cited by 20
Immunological profiles of human oligodendrogliomas define two distinct molecular subtypes
Wu, F., Yin, Y., Fan, W.-H., Zhai, Y., Yu, M., Wang, D., Pan, C., Zhao, Z., Li, G., & Zhang, W. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104410 · Cited by 20
Correlation of PD-L1 and SOCS3 Co-expression with the Prognosis of Hepatocellular Carcinoma Patients
Chen, L., Huang, X., Zhang, W., Liu, Y., Chen, B., Yu, X., Zhang, R., Zhang, M., Feng, J., Liu, S., et al. (2020) · Journal of Cancer · doi:10.7150/jca.46158 · Cited by 20
The Matrisome Genes From Hepatitis B–Related Hepatocellular Carcinoma Unveiled
Chen, W., Désert, R., Ge, X., Han, H., Song, Z., Das, S., Athavale, D., You, H., & Nieto, N. (2021) · Hepatology Communications · doi:10.1002/hep4.1741 · Cited by 20
Zhao, D., Xia, L., Geng, W., Xu, D., Zhong, C., Zhang, J., & Xia, Q. (2021) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.15674 · Cited by 20
New systemic agents for hepatocellular carcinoma: an update 2020
von Felden, J. (2020) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000626 · Cited by 20
Argemí, J., Ponz‐Sarvisé, M., & Sangro, B. (2022) · Advances in cancer research · doi:10.1016/bs.acr.2022.03.002 · Cited by 19
Zaki, M. Y. W., Alhasan, S. F., Shukla, R., McCain, M. V., Laszczewska, M., Geh, D., Patman, G., Televantou, D., Whitehead, A., Maurício, J., et al. (2022) · Liver Cancer · doi:10.1159/000525375 · Cited by 20
Self-citationAoki, T., Nishida, N., Kurebayashi, Y., Sakai, K., Morita, M., Chishina, H., Takita, M., Hagiwara, S., Ida, H., Ueshima, K., et al. (2023) · Liver Cancer · doi:10.1159/000533818 · Cited by 20
Akabane, M., Imaoka, Y., Kawashima, J., & Pawlik, T. M. (2025) · Hepatic Oncology · doi:10.1080/20450923.2025.2493457 · Cited by 21
D’Alessio, A., Cammarota, A., Prete, M. G., Pressiani, T., & Rimassa, L. (2021) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000744 · Cited by 18
Kuwano, A., Yada, M., Narutomi, F., Nagasawa, S., Tanaka, K., Kurosaka, K., Ohishi, Y., Masumoto, A., & Motomura, K. (2022) · Oncology Letters · doi:10.3892/ol.2022.13337 · Cited by 20
Immunotherapy in hepatocellular carcinoma: how will it reshape treatment sequencing?
Cammarota, A., Zanuso, V., Manfredi, G. F., Murphy, R., Pinato, D. J., & Rimassa, L. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221148029 · Cited by 19
Zhu, H., Feng, J.-K., Xiang, Y., Wang, K., Zhou, L.-P., Liu, Z., Cheng, Y., Shi, J., Guo, W., & Cheng, S. (2023) · BMC Cancer · doi:10.1186/s12885-023-11003-0 · Cited by 19
ElBadre, H. M., El-Deek, S. E. M., Ramadan, H. K., Elbadr, M. M., Sabry, D., Ahmed, N. M., Ahmed, A. M., & El-Mahdy, R. I. (2023) · APOPTOSIS · doi:10.1007/s10495-023-01863-z · Cited by 18
Chen, X., Liu, X., & Du, S. (2023) · Cancers · doi:10.3390/cancers15205046 · Cited by 19
Rahdan, F., Saberi, A., Saraygord‐Afshari, N., Hadizadeh, M., Arjmand, T. F., Ghanbari, E., Dianat‐Moghadam, H., & Alizadeh, E. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e39489 · Cited by 18
Li, M., Tang, Y., Gong, Y., Cheng, W., Li, H., Kong, F.-E., Zhu, W., Liu, S., Huang, L., Guan, X., et al. (2019) · BMC Cancer · doi:10.1186/s12885-019-6041-2 · Cited by 18
Jayant, K., Habib, N., Huang, K., Warwick, J., & Arasaradnam, R. P. (2020) · Diagnostics · doi:10.3390/diagnostics10050338 · Cited by 18
Integrating Genomics Into Clinical Practice in Hepatocellular Carcinoma: The Challenges Ahead
Pillai, A. A., Ahn, J. C., & Kulik, L. (2020) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000000843 · Cited by 19
Application of Immunotherapy in Hepatocellular Carcinoma
Miao, L., Zhang, Z., Ren, Z., & Li, Y. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.699060 · Cited by 17
Ogawa, K., Kanzaki, H., Chiba, T., Ao, J., Qiang, N., Ma, Y., Zhang, J., Yumita, S., Ishino, T., Unozawa, H., et al. (2022) · Journal of Cancer · doi:10.7150/jca.71494 · Cited by 19
Kurebayashi, Y., Sugimoto, K., Tsujikawa, H., Matsuda, K., Nomura, R., Ueno, A., Masugi, Y., Yamazaki, K., Effendi, K., Takeuchi, H., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-0479 · Cited by 18
Hallmarks of liver cancer: Therapeutic implications
Llovet, J. M., Pinyol, R., Affò, S., Yarchoan, M. M., Gores, G. J., Kelley, R. K., Lowe, S. W., Sia, D., & Villanueva, A. (2026) · Cell · doi:10.1016/j.cell.2026.03.001 · Cited by 19
Self-citationLin, P., Gao, R., Wen, R., He, Y., & Yang, H. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.715460 · Cited by 18
Metadata
- Authors
- Sia, D., Jiao, Y., Martinez-Quetglas, I., Kuchuk, O., Villacorta-Martin, C., Castro de Moura, M., Putra, J., Camprecios, G., Bassaganyas, L., Akers, N., Losic, B., Waxman, S., Thung, S. N., Mazzaferro, V., Esteller, M., Friedman, S. L., Schwartz, M., Villanueva, A., & Llovet, J. M.
- Affiliations
- Tisch Cancer Institute (US)
- Hospital Clínic de Barcelona (ES)
- University of Milan (IT)
- Institució Catalana de Recerca i Estudis Avançats (ES)
- Corresponding author
- Llovet, Josep M.
- ORCID
- Venue
- Gastroenterology
- Publisher
- Elsevier BV
- Published
- 2017-09
- Volume
- 153
- Issue
- 3
- Pages
- 812-826
- ISSN
- 0016-5085 (ISSN-L)
- PMC
- PMC12166766
- OpenAlex
- W2626033245
- Cited by
- 976
- References
- 46
- Citations by year
- 2026: 65 · 2025: 82 · 2024: 124 · 2023: 136 · 2022: 155 · 2021: 188 · 2020: 104 · 2019: 72 · 2018: 41 · 2017: 9
- FWCI
- 27.37
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Gastroenterology (acceptedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (acceptedVersion, cc-by-nc-nd)
- Funders
- Tisch Cancer Institute (P30 CA196521)
- US Department of Defense (CA150272P3)
- European Commission Framework Program 7 (259744)
- Horizon 2020 Program (667273–2)
- Asociación Española Contra el Cáncer
- Samuel Waxman Cancer Research Foundation
- Spanish National Health Institute (SAF2013–41027)
- Grup de Recerca Consolidat–Recerca Translacional en Oncologia Hepàtica
- AGAUR (SGR 1162)
- European Commission HEPCAR
- Onlus Prometeo
- Hepato-Oncology Research Project
- Istituto Nazionale Tumori
- National Cancer Institute
- IRCCS Foundation
- Juan de la Cierva Fellowship
- Associazione Italiana per la Ricerca sul Cancro
- Italian Ministry of Health
- National Institutes of Health (R01DK56621)
- American Association
- Liver Diseases Foundation Alan Hofmann Clinical and Translational Award
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
- Health Sciences › Medicine › Epidemiology › Hepatitis B Virus Studies
- Keywords
- hepatocellular carcinoma, tumor immune microenvironment, immune cell infiltration, PD-1, T cell exhaustion, TGF-β1, chromosomal abnormalities, cancer mutations, tumor-infiltrating immune cells, immune checkpoint inhibitors, tumor subtypes, gene expression profiling, non-negative matrix factorization, tides
- MeSH terms
- Aged, Female, Carcinoma, Hepatocellular, Humans, Immune Tolerance, Immunohistochemistry, Liver Neoplasms, Male, Middle Aged, Mutation, Signal Transduction, Gene Expression Regulation, Neoplastic, Immunophenotyping, Lymphocytes, Tumor-Infiltrating, DNA Methylation, beta Catenin, Transforming Growth Factor beta1, Adaptive Immunity, Tumor Microenvironment, Transcriptome, B7-H1 Antigen, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
